Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HRS-9563 in Mild to Moderate Hypertension
NCT07297797Phase 2Active, not recruiting
- Sponsor
- Fujian Shengdi Pharmaceuticals
- Start
- Jan 2026
- Primary completion
- Dec 2026
- Modality
- Antisense DNA, MicroRNA (miRNA), Antisense Oligonucleotides (ASOs)
- Countries
- 1
01
Overview
A Phase 2 trial of HRS-9563 in hypertension (HTN), sponsored by Fujian Shengdi Pharmaceuticals. Started Jan 2026; status: active, not recruiting.
02
Drugs
HRS-9563
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT07297797.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07297797.